BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis

marrio31/iStock via Getty Images Shares of BridgeBio (NASDAQ:BBIO) are trading surprisingly poorly this year, despite the company moving toward the launch of acoramidis (pending FDA approval in late November), strengthening its balance sheet, reporting updated positive phase 2 data of infigratinib, announcing the spinout of its oncology unit, and more recently, spinning out several of its early-stage rare disease drugs into a new company called GondolaBio. The HELIOS-B trial of Alnylam’s (ALNY) Amvuttra ...